Global Presence

한미약품에 대한 신뢰와 사랑을 언제나 보내주시는 고객 여러분께 깊은 감사의 말씀을 드립니다.

Hanmi Pharmaceuticals has been producing Cephalosporin APIs since 1987 and supplying them to more than 100 companies in over 40 countries all over the world. Especially in Europe, Hanmi is sustaining long and solid business relationships with the clients in the France, Italy, Germany, Spain, Portugal, Greece, and Poland. In Asia-Pacific region, Japan takes the lead in API trading and Thailand, Indonesia, Bangladesh, Pakistan, Egypt, Jordan, Turkey, and UAE are following up. In American territory, Hanmi mainly deals with the local finished dosage manufacturers based on USA and Mexico.

Worldwide Business Relationship

ASIA:China,HongKong,Taiwan,Japan,Vietnam,Thaiand,Cambodia,Malaysia,Singapore,Indonesia,Philipines,Bangladeshi,india|America:USA,Mexico,Costa Rica,Cuba,Dominica Rep.,Guatemala|EU:EUmore then 10countries|Africa:Egypt,Libya,Nigeria|Middle East:Afghanistan,Yemen,Pakistan,Iran

USA, Mexico, Costa Rica, Dominica Rep., Guatemala, Colombia, Panama, Honduras, El Salvador, Bolivia, Nicaragua, Jamaica
EU-more than 10countries
China, Japan, Vietnam, Thailand, Malaysia, Singapore, Indonesia, Philippines, Bangladesh, India
Middle East
Pakistan, Jordan, Kazakhstan, UAE
Egypt, South Africa, Tunisia

Newly built manufacturing plants provides capabilities to produce several key innovative drug APIs as well as intermediates with highly innovative equipment and technologies, according to the EU-GMP/ cGMP quality requirements and safety standards. With these experiences and facilities, Hanmi teams are open to discuss CMO & CDMO opportunities with future global partners in the fields of sterile APIs, oral solid dosage, injectable, and innovative drug APIs & key intermediates.

Recently, a significant focus has been on sales of FDC (Fixed dose combination) products such as Amlodipine+Losartan, Amlodipine+Losartan+Rosuvastatin, Amlodipine+Losartan+Chlorthalidone, Rosuvastatin+Ezetimibe, and Tamsulosin+Tadalafil to global partners. Furthermore, the first quadra-combinant product in the world, Amlodipine+Losartan+Rosuvastatin+Ezetimibe, has been launched in 2021 and this achievement led us to step out further in the industry. Being encouraged these achievements, Hanmi will continuously put efforts to find the global markets with demands as well as local business partners in other parts of the world in order to prosper FDC pipeline products.

Simultaneously, Hanmi is either putting significant investments & focus on finding partnership opportunities on our platform technologies and subordinative products from its developmental pipeline which are known as LAPSCOVERY (Long-Acting Protein/Peptide Technology) and ORASCOVERY (Oral Oncology Product Technology), to make contribution to the development of next generation new drugs.

If you have any questions or feedback, please click the following link Contact us